AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance]
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: Yahoo! Finance
?demand for newer immunology drugs Skyrizi and Rinvoq and a smaller-than-expected ?decline in sales of its older medicine Humira. The drugmaker has been relying on Skyrizi and Rinvoq ?to counter a drop in Humira sales, which have been facing competition from cheaper biosimilars, or near copies of a biological drug. Humira was once the world's top-selling drug, with peak global sales of more than $21 billion in 2022 before ?it lost patent exclusivity in ?the U.S. Since then, the company has also spent more than $20 billion on acquisitions, and plans to spend another $10 billion over ?the next decade, including building four new manufacturing plants in the U.S. AbbVie expects adjusted annual profit per share of between $14.37 and $14.57, higher than analysts' average estimate of $14.24, according ?to data compiled by LSEG. It also posted better-than-expected fourth-quarter profit and revenue ?on Skyrizi and Rinvoq demand, and a surprise beat for Humira for the first time in near
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating [Yahoo! Finance]Yahoo! Finance
- Evolus (NASDAQ:EOLS) was given a new $15.00 price target on by analysts at Mizuho.MarketBeat
- AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance Canada]Yahoo! Finance Canada
- Evolus (NASDAQ:EOLS) had its price target lowered by analysts at HC Wainwright from $20.00 to $13.00. They now have a "buy" rating on the stock.MarketBeat
- How A New Price Target Is Shaping The Evolus (EOLS) Story [Yahoo! Finance]Yahoo! Finance
EOLS
Earnings
- 11/5/25 - Beat
EOLS
Sec Filings
- 1/9/26 - Form 8-K
- 12/29/25 - Form 4
- 12/29/25 - Form 4
- EOLS's page on the SEC website